ArticlePeerJ2025
Identification and experimental verification of necroptosis-related prognostic gene signature and characterization of tumor immune infiltration in lung squamous cell carcinoma.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung squamous cell carcinoma (LUSC) is a common and aggressive malignancy. Necroptosis, a regulated mode of cell death, has been implicated in tumor immunity and oncogenic processes, yet the mechanistic involvement of necroptosis-related genes (NRGs) in LUSC pathogenesis remains unclear, necessitating systematic evaluation of their biological and clinical relevance. Methods and Results: Clinical and transcriptomic data of LUSC patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were subjected to integrative analyses. Screening of the Kyoto Encyclopedia of Genes and Genomes (KEGG) database identified 159 NRGs, among which 35 differentially expressed NRGs (DENRGs) were associated with necroptosis, apoptosis, and immune signaling pathways. Cox regression combined with Least Absolute Shrinkage and Selection Operator (LASSO) analysis yielded three NRGs (CAMK2A, CHMP4C, and PYGB) strongly associated with patient prognosis. Based on these genes, a prognostic model was constructed to stratify patients into high- and low-risk subgroups with distinct survival patterns. External dataset validation demonstrated moderate predictive accuracy. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC) confirmed abnormal expression of the three genes in LUSC tissues. Additional analyses revealed correlations of these NRGs with immune infiltration, immune checkpoint activity, tumor mutation burden (TMB), and microsatellite instability (MSI). Conclusions: A three-gene NRG signature was identified as a prognostic marker in LUSC. These genes appear to influence disease progression and the immune microenvironment, highlighting their potential as therapeutic targets and as a foundation for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.